U.S. markets close in 5 minutes
  • S&P 500

    3,853.64
    +12.17 (+0.32%)
     
  • Dow 30

    30,937.23
    -59.75 (-0.19%)
     
  • Nasdaq

    13,629.57
    +86.51 (+0.64%)
     
  • Russell 2000

    2,158.32
    -10.44 (-0.48%)
     
  • Crude Oil

    52.77
    +0.50 (+0.96%)
     
  • Gold

    1,852.80
    -3.40 (-0.18%)
     
  • Silver

    25.36
    -0.19 (-0.75%)
     
  • EUR/USD

    1.2145
    -0.0030 (-0.24%)
     
  • 10-Yr Bond

    1.0400
    -0.0510 (-4.67%)
     
  • GBP/USD

    1.3669
    -0.0015 (-0.11%)
     
  • USD/JPY

    103.7630
    +0.0020 (+0.00%)
     
  • BTC-USD

    33,273.38
    -173.86 (-0.52%)
     
  • CMC Crypto 200

    669.02
    -7.88 (-1.16%)
     
  • FTSE 100

    6,638.85
    -56.22 (-0.84%)
     
  • Nikkei 225

    28,822.29
    +190.84 (+0.67%)
     

Cabaletta Bio to Present at Multiple Upcoming September Investor Conferences

Cabaletta Bio
·2 min read

PHILADELPHIA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside chats at the following upcoming September investor conferences:

  • Morgan Stanley 18th Annual Global Healthcare Conference on Monday, September 14, 2020 at 3:00 p.m. ET.

  • H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 4:30 p.m. ET.

A live webcast of the presentations will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentations, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com